PDCD1 and classic Hodgkin lymphoma: Decitabine increased the efficacy of anti-PD-1 antibody in refractory cHL, even in patients with anti-PD-1 monotherapy resistance.613,614 The completed clinical trials with HMAs plus other treatments, including chemotherapy, PD-1 inhibitor, are listed in Table 2.